Article

Daily Medication Pearl: Moxifloxacin Hydrochloride (Avelox)

Moxifloxacin hydrochloride (Avelox) is indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria.

Medication Pearl of the Day: Moxifloxacin Hydrochloride (Avelox)

Indication: Moxifloxacin hydrochloride (Avelox) is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in community acquired pneumonia, skin and skin structure infections: uncomplicated and complicated intra-abdominal infections, plague, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis.

Insight:

  • Dosing: 400 mg 7 to 14 days
  • Dosage forms: Tablets of moxifloxacin hydrochloride (equivalent to 400 mg moxifloxacin). Injection of moxifloxacin hydrochloride (equivalent to 400 mg moxifloxacin) in 0.8% sodium chloride solution in a 250 mL flexbag.
  • Adverse events: Most common reactions (3% or greater) were nausea, diarrhea, headache, and dizziness.
  • Mechanism of action: The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair, and recombination.

Source: AVELOX (moxifloxacin hydrochloride (fda.gov)

Related Videos
Senior Doctor is examining An Asian patient.
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC